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Retinoblastoma (RB) is the most common eye cancer 
in children aged <15 years, accounting for 3% of 
all cancers in children.[1] Diagnosis is usually made 
at a young age (<2 years). The tumour presents 
unilaterally in the majority of patients (70 - 75%).[1] 
The majority of bilateral tumours (75%) and about 15% of unilateral 
tumours are hereditary, and these patients usually present with 
more than one tumour in one or both eyes.[2] RB appears to be more 
common in Africa and Latin America.[3,4] Survival is excellent in 
developed countries, where the survival rate is >95%, but it is only 
~50% in developing countries, mostly because of late diagnosis and 
extraocular disease at diagnosis.[1,4-6]
Late diagnosis of childhood cancer is common in developing 
countries, and it is important to document the outcome of children 
with advanced RB who were treated according to standard treatment 
protocols.[4,5] In South Africa (SA), several public health interventions 
have been introduced in the past 20 years, particularly to improve 
the healthcare of children. Of note is the free healthcare for children 
under 6 years of age introduced in 1994 and community service 
for doctors since 1998 in all regions of the country, including rural 
hospitals with human resource shortages.[7-9]
The National Department of Health (NDoH) and the Childhood 
Cancer Foundation (CHOC), acting in collaboration, introduced 
an awareness programme with posters depicting the danger signs 
of childhood cancer in primary healthcare clinics in 2000.[10] 
Doctors from the universities of the Witwatersrand and Pretoria 
also undertook outreach visits to referral hospitals in 2001 - 2004 to 
train staff in early detection of childhood cancer, and especially to 
check for the absence of a red reflex in the eye in order to detect RB 
early. Parents were encouraged to note absent red reflex of an eye in 
photos taken with a flashlight. A satellite paediatric oncology unit 
(POU) of the POU at Kalafong Hospital, Pretoria, was established in 
Polokwane, Limpopo Province, in 2007 to assist with early diagnosis, 
treatment, and referral (only if necessary) as part of improving cancer 
care for children.
The aim of this research was to compare stage and outcome of 
children with RB during two time periods, namely 1993 - 2000, 
before the outreach interventions, and 2001 - 2008, after the outreach 
interventions.
Patients and methods
Setting
Kalafong Hospital, a large regional hospital, housed the POU 
before it was moved to Steve Biko Academic Hospital, Pretoria, 
in December 2009. The POU was established at Kalafong in 1993 
and served all children with cancer in the Northern Gauteng 
region and the provinces of Mpumalanga and Limpopo who were 
enrolled on prospective treatment protocols between 1993 and 
2008.
Design
We prospectively documented the following data for all patients 
treated for RB between 1993 and 2008: demographics (date of 
birth, age, gender and place of birth), medical history, clinical 
findings, diagnostic procedures, treatment protocol and referral 
pathway.
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Introduction. Retinoblastoma (RB) is the most common eye cancer in children. Early detection is necessary for cure.
Objective. To compare stage and outcome of children with RB treated at Kalafong Hospital, Pretoria, South Africa (SA), during two time periods 
(1993 - 2000 and 2001 - 2008, after outreach interventions in 2000 and introduction of compulsory community service for doctors in 1998).
Methods. Data collected included demography (age, gender, date of birth), stage and treatment received. The main outcome measure was 
disease-free survival and the study end-point was 60 months after diagnosis.
Results. There were 51 patients during the time period 1993 - 2000 (group 1) and 73 during 2001 - 2008 (group 2), with median ages 
of 32 and 26 months, respectively (marginally significantly younger in group 2; p=0.046). In group 1, the majority (57%) presented with 
advanced disease (stages III and IV), with a decline in this proportion in group 2 (40%) indicating a downward but not significant trend 
(p=0.075). Bilateral disease was diagnosed in 22% of patients in group 1 and 33% in group 2. Overall survival was 33% and 43% for groups 
1 and 2, respectively. Excluding absconding patients, event-free survival was 50% in group 1, improving to 68% in group 2 (not statistically 
significant; p=0.18). Fewer patients needed radiotherapy during the second period (statistically significant; p=0.04), probably because of 
less advanced disease.
Conclusion. Poor outcome is probably a result of late diagnosis. It is important to implement a strategy that will ensure early diagnosis and 
optimal management of RB in SA.
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Staging
The diagnostic procedures for all patients 
included eye examination under general 
anaesthesia, a computed tomography scan 
of the eyes and skull, bone scintigraphy 
(except in cases of intraocular disease), 
lumbar puncture for cerebrospinal fluid 
cell examination and count, and bone 
marrow aspiration. The patients were staged 
according to the Grabowski-Abramson 
classification and the Ellsworth Clinic 
pathological classification, as follows:[11]
• Stage I. Intraocular disease – amenable to 
local therapy or eye enucleated
• Stage II. Orbital disease (IIa orbital 
involvement only; IIb post-laminar 
optic nerve involvement as well) – eye 
enucleated, microscopic residual tumour, 
tumour in excision line of the optic nerve
• Stage III. Central nervous system involve-
ment – regional extension and central 
nervous system metastasis
• Stage IV. Haematogenous metastatic 
disease
• Stage V. Bilateral disease with or without 
metastasis.
Treatment outline
Patients with stage I disease received either 
local therapy (cryotherapy or brachytherapy) 
or enucleation, depending on the size of 
the intraocular tumours and whether it 
was possible to salvage vision. All patients 
except those with intraocular disease (stage 
I) received neoadjuvant chemotherapy. Enu-
cleation or exenteration was performed 
after two cycles of chemotherapy. Patients 
with advanced disease (stages III and IV) 
received either cranial-spinal radiotherapy 
(external beam radiotherapy) after six cycles 
of chemotherapy had been completed or 
iodine-125 brachytherapy in Cape Town.[12,13]
The first 12 patients received treatment 
according to treatment protocol 1 (1993 - 
1994) with the following drugs: ifosfamide 
2 000 mg/m2, carboplatin 550 mg/m2 and 
etoposide 150 mg/m2 every 4 weeks for six 
cycles. Patients with stages II - IV disease 
also received intrathecal therapy, consisting 
of methotrexate, cytarabine and Solu-Cortef 
weekly for 6 weeks. Owing to associated 
severe haematological toxicity (World Health 
Organization grade 4), the treatment was 
changed to treatment protocol 2 (1995 - 2008) 
with the following drugs: vincristine 1.5 mg/
m2, etoposide 300 mg/m2 and carboplatin 
550 mg/m2 every 4 weeks for six cycles with 
intrathecal therapy weekly for 6 weeks.
Patient groups
The patients were assigned to two groups 
for two time periods, defined as group 1 
Table 1. Demography and management of patients 
Group 1,
1993 - 2000
Group 2,
2001 - 2008 p-value
Patients, N 51 73
Age (months), median (range) 32 (3 - 83) 26 (0 - 119) 0.046 (NS)
Male/female ratio 2.4:1 1.7:1 0.32 (NS)
Eyes amenable to local therapy, n (%) 8 (15.7) 15 (20.5) 0.35 (NS)
Eyes enucleated, n (%) 41 (80.4)* 56 (76.7)† 0.62 (NS)
Radiotherapy, n (%) 18 (35.3) 18 (24.7) 0.004 (SS)
Unilateral/bilateral ratio 3.6:1 2.2:1 0.22 (NS)
NS = not statistically significant; SS = statistically significant.
*2% surgery refusal, 2% unknown.
†3% surgery refusal, 1% unknown.
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Fig. 1. Stage at diagnosis of RB for the two study groups. (RB = retinoblastoma; group 1: 1993 - 2000; 
group 2: 2001 - 2008.)
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Fig. 2. Overall survival for the two study groups, including absconding patients. (Group 1: 1993 - 2000; 
group 2: 2001 - 2008.)
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for the time period 1993 - 2000, before 
the outreach interventions, and group 2 
for the time period 2001 - 2008, during 
and after the outreach interventions. 
The second period followed several 
educational outreach activities to referral 
centres by staff from the universities of 
the Witwatersrand and Pretoria, as well 
as interventions undertaken to improve 
early diagnosis of childhood cancer by 
the joint CHOC and NDoH awareness 
campaign.[10] The joint South African 
Children Cancer Study Group and NDoH 
awareness campaign distributed posters 
depicting the danger signs of childhood 
cancer to all primary care clinics, district 
and regional hospitals, as well as central 
hospitals in the country.
Study end-point
The study end-point was defined as 60 
months (5 years) after diagnosis.
Statistical analysis
Continuous variables were described using 
medians and ranges, and categorical variables 
using frequency distributions and ratios. 
Comparisons of continuous variables between 
binary variables were performed using the 
Mann-Whitney U-test. Contingency tables 
were used to analyse the association between 
group and a binary classification of staging. 
Pearson’s χ2 test was used to determine 
whether differences were significant or not. 
Kaplan-Meier plots were used to calculate 
overall survival, and log-rank tests to compare 
survival rates for different subgroups of 
patients. A significance level of p<0.05 was 
applied throughout.
Ethics
The Research Ethics Committee, Faculty 
of Health Sciences, University of Pretoria, 
approved this retrospective review of patient 
records with a waiver of informed consent.
Results
One hundred and twenty-four patients 
(51 in group 1 and 73 in group 2) were 
included in the final data analysis (Table 
1). Ten patients were excluded owing to 
incomplete data (4 patients), transferral to 
another treatment facility (4 patients) and 
absconding within an hour from the POU 
(2 patients).
The median age was 35 months for the 
combined patient population with unilateral 
disease and 21 months for patients with 
bilateral disease (Table 1). The median 
age was 32 months for group 1 and 26 
months for group 2, the second group being 
slightly younger, with a difference that was 
marginally statistically significant (p=0.046). 
Eleven patients (22%) in group 1 and 23 
(33%) in group 2 had bilateral disease. The 
majority (57%) in group 1 had advanced 
disease (29/51 patients: 19 had stage IV 
disease, 7 had stage III disease and 3 had 
metastatic bilateral disease (stage V)). There 
was a downward but not yet statistically 
significant trend (40%) in group 2 (29/73 
patients: 14 had stage IV disease, 5 had stage 
III disease and 10 had metastatic bilateral 
disease) (p=0.075) (Fig. 1). More boys than 
girls were affected, although the difference 
was not statistically significant (male/female 
ratio 2.4:1 for group 1 and 1.7:1 for group 2) 
(Table 1).
Only 8 eyes were amenable to local 
therapy in group 1 v. 15 eyes in group 2 
(Table 1). Thirty-eight eyes were enucleated 
and 3 eyes were exenterated in group 1 v. 52 
eyes enucleated and 3 eyes exenterated (1 
patient with bilateral disease) in group 2. The 
parents of three patients refused surgery (1 
in group 1, 2 in group 2), and type of surgery 
was not documented for one child in each 
group. Fewer patients received radiotherapy 
in the second group (18/73 patients in group 
2 v. 18/51 in group 1), which was statistically 
significant (p=0.004). Fourteen patients 
received external beam radiation in group 
1 v. only 6 in group 2, while only 4 patients 
received iodine-125 brachytherapy in group 
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Fig. 3. Overall survival for the two study groups, excluding absconding patients. (Group 1: 1993 - 2000; 
group 2: 2001 - 2008.)
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Fig. 4. Survival according to stage at diagnosis for group 1, excluding absconding patients (1993 - 2000).
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1, increasing to 12 patients in group 2. 
Of the patients who received iodine-125 
brachytherapy, 2 had stage I disease and 14 
bilateral disease. Unilateral disease was more 
common, as expected, with a ratio of 3.6:1 in 
the first period and 2.2:1 in the second.
Overall survival was 33% and 43% for 
groups 1 and 2, respectively, with a trend 
towards better survival in the second 
period (not statistically significant) (Fig. 
2). If absconding patients were excluded, 
event-free survival was 50% for group 1 
and improved to 68% for group 2, not yet 
statistically significant but with a trend 
towards significance (p=0.18) (Fig. 3). 
Absconding patients were patients lost to 
follow-up during active treatment or on 
completion of treatment. Eight patients 
(16%) absconded from active treatment 
and 5 (10%) were lost to follow-up after 
treatment in group 1, while 5 patients (7%) 
absconded during treatment and 13 (18%) 
were lost to follow-up in group 2. Limited 
disease had an excellent outcome, with 100% 
disease-free survival for patients with stage 
I disease in both groups and 79% and 84% 
for stage II disease in groups 1 and 2, 
respectively (Figs 4 and 5). The mean time 
to absconding for groups 1 and 2 combined 
was 31 months (median 14 months, range 
6 - 129). Overall survival for children 
with unilateral disease was 59% v. 62% for 
bilateral disease (combined data for groups 1 
and 2, excluding absconders). As mentioned 
above, 13/34 patients with bilateral disease 
had metastasis at diagnosis (38%) (Fig. 6).
The major reason for poor outcome was 
progression of disease (9 patients in group 
1, 11 in group 2), followed by relapse in 
5 patients in each group (28% and 22% 
for groups 1 and 2, respectively). Other 
reasons included sepsis in 4 patients (2 
with limited and bilateral disease, 2 with 
metastatic disease), an underlying congenital 
heart lesion in 1 patient, underlying renal 
disease in 1 patient, and unexpected death 
of 1 patient at home. One of the patients 
with limited bilateral disease, who died of 
sepsis (Pseudomonas aeruginosa), also had 
concomitant HIV infection.
Discussion
Limited disease at diagnosis of RB offers 
the best chance of cure, with >90% of 
children surviving in developed countries, 
and also ensures that these children qualify 
for conservative eye-sparing treatment 
with decreased morbidity, especially as it is 
possible to avoid external beam radiation 
therapy.[1] Late diagnosis and advanced 
disease are common in developing countries, 
however, and associated with an increased risk 
of extraocular disease and poor outcome.[4,5] 
Canturk et al.[14] reported estimated survival 
for low-income countries as 40%, for lower 
middle-income countries (LMICs) as 77% 
and for upper middle-income countries 
(UMICs) as 79%. In our study, survival rates 
were 50% and 68%, respectively, in the two 
time periods, excluding absconding patients, 
which is lower than the survival achieved 
in either LMICs or UMICs. Of concern is 
that about 25% of patients in each study 
period absconded during or after treatment, 
which lowered overall survival to 33% and 
43%, respectively, for the two time periods 
and contrasts with an Indian report for 
2008 - 2011, where a statistically significant 
downward trend in the rate of absconders 
was seen.[15] Kumar et al.[15] further reported 
that the major reasons for abandonment of 
treatment were either financial constraints 
(30%) or refusal of enucleation (20%), 
which was probably also true for our study 
population.
The gender distribution of our patients 
was similar to that in developed countries, 
but the unilateral v. bilateral ratio was 73% 
v. 27%. This ratio correlated with a previous 
SA study in the 1970s in which Freedman 
and Goldberg[16] found that 82% of patients 
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Fig. 5. Survival according to stage at diagnosis for group 2, excluding absconding patients (2001 - 2008).
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Fig. 6. Overall survival of patients with unilateral v. bilateral disease.
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had unilateral disease, which was different from developed countries, 
which had a 60% v. 40% ratio. Age was higher for unilateral disease 
(35 months) than for bilateral disease (21 months), which has been 
reported previously in developing countries, but overall our patients 
were older than those in developed countries.[1,4]
Canturk et al.[14] further reported that the presence of metastatic 
disease was significantly associated with physician density. There is 
a general shortage of health professionals in SA state hospitals, and 
Hlangani[17] reported in 2002 that more than 29 000 doctors’ posts 
were vacant throughout hospitals in SA. This may explain the large 
proportion of patients in this study with advanced disease at diagnosis 
(57% for the earlier and 40% for the later time period). Long distances 
from tertiary healthcare facilities that provide comprehensive therapy 
to children with RB are another factor that may result in late 
diagnosis. Access to POUs is available in eight centres in SA, but 
these centres are concentrated mainly in the large cities, whereas the 
majority of the patients in our study were from rural communities, 
far from these cities. The distances between cities and rural areas 
might have caused delays in the referral of these patients as a result 
of transport issues, added to late recognition of the cancer due to low 
physician density.[14,17]
There was improvement between the two study periods, with a 
trend towards more limited disease and better survival in the second 
period. Public healthcare interventions such as free healthcare for 
children under 6 years of age in SA and compulsory community 
service for doctors since 1998 did not seem to have influenced early 
diagnosis of childhood cancer significantly, which was contrary to 
our expectations.[7-9]
Early diagnosis campaigns are probably the solution.[18,19] Parents 
should be taught to look for the presence of a red reflex of the eye 
by taking a flash photograph of their children younger than 1 year 
of age and to report the absence of this reflex, or the presence of any 
white spot in the eye, at the nearest primary care facility, which may 
improve early diagnosis. Healthcare workers also need training to 
increase their awareness that leucocoria in a young child is probably 
due to RB, and refer these patients urgently to a tertiary healthcare 
facility for further management. In Honduras information about 
leucocoria was distributed at vaccination clinics, targeting mothers 
to recognise the symptoms to improve early diagnosis.[20] Kenya 
launched a 5-year capacity-building national strategy to improve 
the survival of children with RB in 2008.[21] Key components of 
the Kenyan National Retinoblastoma Strategy are efforts to create 
RB awareness among healthcare workers and the public at large, to 
improve diagnostic pathology services, and to implement a support 
programme for families with a child suffering from RB. A similar 
programme is needed in SA to assist in early recognition of RB by 
creating awareness, and ensure optimal care to cure the disease and 
save vision.
Conclusion
Advanced disease in this study was associated with an overall 
survival rate of <70%. A strategy is necessary in SA to ensure that 
children with RB are diagnosed early and that >90% of them are 
cured. This will require mass education programmes directed at the 
public at large to sensitise them to the significance of leucocoria, 
as well as at healthcare workers to teach them to diagnose the 
disease early and refer patients timeously to the multidisciplinary 
teams at the existing POUs in SA, of which the majority initiated a 
standardised RB management protocol in January 2013.
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